Author(s) Scott, Gemma; Mahdi, Ali Jassem; Alikhan, Raza, et al.

Journal British Journal of Haematology. Date of publication 2015 Mar 1;volume 168(5):639-645.

Abstract Superficial vein thrombosis (SVT) was considered to be a benign and self-limiting condition. However, it is now appreciated that a significant proportion of those presenting with SVT will have concomitant deep vein thrombosis or pulmonary embolism, or are at significant risk of developing deep venous thromboembolism. Potential therapeutic options include topical preparations, compression therapy (stockings, bandages), medication such as non-steroidal anti-inflammatory drugs (NSAIDs) or anticoagulants (therapeutic or prophylactic doses) and surgery, ligation or stripping, of superficial veins. The treatment of choice is therapeutic/intermediate dose low molecular weight heparin or prophylactic dose fondaparinux administered for 4-6 weeks. The cost-effectiveness of treatment is a concern and more targeted therapy is required. © 2014 John Wiley & Sons Ltd.

Source ID (e.g. PMID): 25521017